Recent articles
Has Your Portfolio Moved Beyond Genomics Yet?
There's plenty of untapped potential left in genomics, but there are quite a few other omics investors need to know about heading into 2020.
Is AnaptysBio a Buy?
Investors have lost faith in the biopharma, which is sitting at its lowest market cap in two years. But Wall Street may be overlooking a significant catalyst from a partnered asset.
Will a $48 Billion Global Settlement End U.S. Opioid Crisis Lawsuits?
A settlement in a closely watched Ohio case averted a federal trial and paves the way to a nationwide settlement -- if drug companies shorten their payment timelines.
Is Incyte a Buy?
The company is a one-trick pony, but should generate profits for the foreseeable future. Can the pipeline finally come through for investors?
Is Amicus Therapeutics a Buy?
The gene therapy stock is trading at its lowest level in over two years. It recently announced preliminary third-quarter 2019 operating results.
Here's Why Teva Pharmaceutical Soared Today
The company announced an unexpectedly favorable settlement in a lawsuit related to the opioid epidemic.
Is Aerie Pharmaceuticals a Buy?
The small-cap company's shares have fallen 64% in the last year, but a promising drug portfolio might signal an opportunity for investors with a long-term mindset.
How Much U.S. Electricity Will Come From Renewables in 2030?
Most people are way too pessimistic relative to what's likely in store for American renewable energy.
Investors Rejoice: U.S. Renewables Could Top Coal by 2022
A surge in wind power can blow coal down the rankings in the near future. These renewable energy stocks could benefit.
Can This High-Yield Utility Elbow Its Way to Renewable Energy Leadership?
American Electric Power is one of the largest utility holding companies in the United States, but it's lagging behind its peers in renewable energy.
Here's Why Assembly Biosciences Stock Soared Today
The company reported promising updates for two important pipeline programs.
Amyris Files First-Half 2019 Reports: What Investors Need to Know
The filings provide a glimpse of the company's struggles. Can cannabinoids pull the business out of the doldrums?
3 Things Repligen Investors Need to Watch
The year may be drawing to a close, but this biomanufacturing stock -- and any investor interested in it -- has plenty to look forward to.
Why Amarin Investors Have Their Eyes on Nov. 14
An important regulatory milestone has been pushed back to late December, although investors will be awaiting voting results from a meeting in mid-November.
Here's Why Steel Stocks Erupted for Big Gains on Friday
The United States and China reached a partial deal in the ongoing trade war.
Here's Why Aerie Pharmaceuticals Rose as Much as 21.8% Today
A new slide deck shows reasons for optimism.
Here's Why Nektar Therapeutics Stock Fell as Much as 11.6% Today
An analyst downgrade is only adding to the company's woes.
Here's Why Puma Biotechnology Tumbled Today
An analyst downgrade and a departing executive make for a bad day.
Here's Why Livongo Health Gained as Much as 16.9% Today
A big contract could keep fueling growth.
Here's Why Myriad Genetics Jumped 21.7% in September
The genetic-testing stock can't seem to escape the trap of volatility.